Dr Fehrenbacher speaks at a SABCS 2017 press session about data from the randomised, phase III NSABP-B-47 clinical trial.

Adding trastuzumab (Herceptin) to standard adjuvant chemotherapy did not improve invasive disease–free survival for patients with early-stage breast cancer found to have low levels of HER2, as defined as immunohistochemistry (IHC) 1 or 2 and/or in situ hybridization (ISH) negative.

Watch the video interview for more.